Maravai LifeSciences Holdings (Maravai LifeSciences Holdings) Change In Receivables : $19.9 Mil (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Maravai LifeSciences Holdings Change In Receivables?

Maravai LifeSciences Holdings's change in receivables for the quarter that ended in Mar. 2024 was $17.9 Mil. It means Maravai LifeSciences Holdings's Accounts Receivable declined by $17.9 Mil from Dec. 2023 to Mar. 2024 .

Maravai LifeSciences Holdings's change in receivables for the fiscal year that ended in Dec. 2023 was $84.4 Mil. It means Maravai LifeSciences Holdings's Accounts Receivable declined by $84.4 Mil from Dec. 2022 to Dec. 2023 .

Maravai LifeSciences Holdings's Accounts Receivable for the quarter that ended in Mar. 2024 was $36.7 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Maravai LifeSciences Holdings's Days Sales Outstanding for the three months ended in Mar. 2024 was 52.16.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Maravai LifeSciences Holdings's liquidation value for the three months ended in Mar. 2024 was $-53.1 Mil.

Maravai LifeSciences Holdings Change In Receivables Historical Data

The historical data trend for Maravai LifeSciences Holdings's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maravai LifeSciences Holdings Change In Receivables Chart

Maravai LifeSciences Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-1.89

-33.14

-70.39

-22.27

84.40

Maravai LifeSciences Holdings Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															82.41	7.56	3.21	-8.79	17.88

Maravai LifeSciences Holdings Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.9 Mil.

Maravai LifeSciences Holdings (NAS:MRVI) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Maravai LifeSciences Holdings's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	36.685	/	64.179	*	91
=	52.16

2. In Ben Graham's calculation of liquidation value, Maravai LifeSciences Holdings's accounts receivable are only considered to be worth 75% of book value:

Maravai LifeSciences Holdings's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	561.691	-	667.252	+	0.75 * 36.685	+	0.5 * 49.846
=	-53.1

Maravai LifeSciences Holdings Change In Receivables Related Terms

Thank you for viewing the detailed overview of Maravai LifeSciences Holdings's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Maravai LifeSciences Holdings (Maravai LifeSciences Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maravai LifeSciences Holdings Inc (NAS:MRVI) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

MRVI:Mexico MAR:Germany

Address

10770 Wateridge Circle, Suite 200, San Diego, CA, USA, 92121

Website

https://www.maravai.com

Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. The company's segments are Nucleic acid production, Biologics safety testing, and Protein detection. It generates a majority of its revenue from the Nucleic Acid Production that focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

Executives

John A Deford	director	C R BARD INC, 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Rebecca Buzzeo	officer: See Remarks	C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Andrew Burch	officer: See Remarks	C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Martin William E. Iii	officer: See remarks	C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE, SUITE 200, SAN DIEGO CA 92121
Peter Michael Leddy	officer: See Remarks	1620 FARADAY AVE, CARLSBAD CA 92008
Carl Hull	director, officer: Chief Executive Officer	300 N. LASALLE SUITE 5600, CHICAGO IL 60654
Gregory T Lucier	director	C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Kurt Oreshack	officer: General Counsel	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Murali Prahalad	director	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Lisa Sellers	officer: See Remarks	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Susannah Gray	director	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Robert B Hance	director	300 N. LASALLE SUITE 5600, CHICAGO IL 60654
Jessica Hopfield	director	C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Brian Neel	officer: See Remarks	10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Christine Dolan	officer: See Remarks	C/O MARAVAI LIFESCIENCES HOLDINGS, INC., 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121